TGFβ-IN-3

• Description:

  TGFβ-IN-3 (Compound 8) is a long-acting tumor-activating prodrug of TGFβR1 inhibitor. TGFβ-IN-3 can achieve selective drug release in tumors, and the tumor/blood ratio is increased by 2.2 times. TGFβ-IN-3 can be used for the study of colon cancer[1].

• UNSPSC:

  12352005

• Target:

  TGF-β Receptor

• Related Pathways:

  TGF-beta/Smad

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Smiles:

  OC (CCCCCCCCCCCCCCCCC (N[C@H] (C (O) =O) CCC (NCCOCCOCC (NCCOCCOCC (N[C@@H] (CC (C) C) C (N[C@@H] (CO) C (NCC (N[C@@H] (CCCCN) C (NC (C=C1) =CC=C1COC (NCOCCN2C (C3=NN4C (C=C3) =NC=C4C#N) =C (C5=CC (Cl) =C (C=C5) F) N=C2) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O

• Molecular Formula:

  C79H114ClFN16O20

• Molecular Weight:

  1662.30

• References & Citations:

  [1]Zhang Y, et al. Long-Acting Tumor-Activated Prodrug of a TGFβR Inhibitor. J Med Chem. 2021 Nov 11;64 (21) :15787-15798.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  2857845-34-0